Abstract
Obese subjects with visceral adiposity might have multiple abnormalities along the growth hormone (GH)/insulin-like growth factor-1 (IGF-1) axis. The reciprocal relationships between GH secretion and adipose tissue depots can complicate the differential diagnosis between organic GHD and obesity-related decrease in GH secretion in obese individuals. Albeit functional and mainly reversible after weight loss, the low GH status is associated with a higher prevalence of cardiometabolic risk factors and a worse body composition compared with obese individuals with a normal GH/IGF-1 axis. The impairment of GH/IGF-1 axis might be the rationale to consider GH as an adjunctive treatment of obesity, at least in the subset of obese individuals with reduced GH secretory capacity and low circulating levels of IGF-1, in relation to their worse cardiometabolic risk profile, with particular regard to those patients who are candidates for bariatric surgery.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Berryman DE, Glad CA, List EO, Johannsson G (2013) The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations. Nat Rev Endocrinol 9:346–356
Savastano S, Di Somma C, Belfiore A et al (2006) Growth hormone status in morbidly obese subjects and correlation with body composition. J Endocrinol Invest 29:536–543
Savastano S, Di Somma C, Mentone A et al (2006) GH insufficiency in obese patients. J Endocrinol Invest 29(Suppl 5):42–53
Vijayakumar A, Yakar S, Leroith D (2011) The intricate role of growth hormone in metabolism. Front Endocrinol (Lausanne) 2:1–11
Kumar PA, Chitra PS, Lu C et al (2014) Growth hormone (GH) differentially regulates NF-kB activity in preadipocytes and macrophages: implications for GH’s role in adipose tissue homeostasis in obesity. J Physiol Biochem 70:433–440
Vottero A, Guzzetti C, Loche S (2013) New aspects of the physiology of the GH-IGF-1 axis. Endocr Dev 24:96–105
Kawai M, Rosen CJ (2010) The IGF-I regulatory system and its impact on skeletal and energy homeostasis. J Cell Biochem 111:14–19
Frystyk J (2004) Free insulin-like growth factors: measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm IGF Res 14:337–375
Cordido F, Peino R, Peñalva A et al (1996) Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression. J Clin Endocrinol Metab 81:914–918
Di Somma C, Rivellese A, Pizza G et al (2011) Effects of short-term treatment with orlistat on growth hormone/insulin-like growth factor-I axis in obese post-menopausal women. J Endocrinol Invest 34:90–96
Scacchi M, Orsini F, Cattaneo A et al (2010) The diagnosis of GH deficiency in obese patients: a reappraisal with GHRH plus arginine testing after pharmacological blockade of lipolysis. Eur J Endocrinol 163:201–206
Rasmussen MH (2010) Obesity, growth hormone and weight loss. Mol Cell Endocrinol 316:147–153
Di Somma C, Angrisani L, Rota F et al (2008) GH and IGF-I deficiency are associated with reduced loss of fat mass after laparoscopic-adjustable silicone gastric banding. Clin Endocrinol (Oxf) 69:393–399
Savastano S, Di Somma C, Pizza G et al (2011) Liver-spleen axis, insulin-like growth factor-(IGF)-I axis and fat mass in overweight/obese females. J Transl Med 9:136
Fuentes E, Fuentes F, Vilahur G et al (2013) Mechanisms of chronic state of inflammation as mediators that link obese adipose tissue and metabolic syndrome. Mediators Inflamm 2013:1–11
Frystyk J, Brick DJ, Gerweck AV et al (2009) Bioactive insulin-like growth factor-I in obesity. J Clin Endocrinol Metab 94:3093–3097
Stanley TL, Feldpausch MN, Murphy CA et al (2014) Discordance of IGF-1 and GH stimulation testing for altered GH secretion in obesity. Growth Horm IGF Res 24:10–15
Molitch ME, Clemmons DR, Malozowski S et al (2011) Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1587–1609
Colao A, Di Somma C, Savastano S et al (2009) A reappraisal of diagnosing GH deficiency in adults: role of gender, age, waist circumference, and body mass index. J Clin Endocrinol Metab 94:4414–4422
Corneli G, Di Somma C, Baldelli R et al (2005) The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. Eur J Endocrinol 153:257–264
Bredella MA, Utz AL, Torriani M et al (2009) Anthropometry, CT, and DXA as predictors of GH deficiency in premenopausal women: ROC curve analysis. J Appl Physiol 106:418–422
Perotti M, Perra S, Saluzzi A et al (2013) Body fat mass is a strong and negative predictor of peak stimulated growth hormone and bone mineral density in healthy adolescents during transition period. Horm Metab Res 45:748–753
Popovic V (2013) Approach to testing growth hormone (GH) secretion in obese subjects. J Clin Endocrinol Metab 98:1789–1796
Colao A, Di Somma C, Cuocolo A et al (2004) The severity of growth hormone deficiency correlates with the severity of cardiac impairment in 100 adult patients with hypopituitarism: an observational, case-control study. J Clin Endocrinol Metab 89:5998–6004
Colao A, Di Somma C, Cascella T et al (2008) Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects. Eur J Endocrinol 159:389–397
Akanji AO, Smith RJ (2012) The insulin-like growth factor system, metabolic syndrome, and cardiovascular disease risk. Metab Syndr Relat Disord 10:3–13
Di Somma C, Pivonello R, Pizza G et al (2010) Prevalence of the metabolic syndrome in moderately-severely obese subjects with and without growth hormone deficiency. J Endocrinol Invest 33:171–177
Bredella MA, Torriani M, Thomas BJ et al (2009) Peak growth hormone-releasing hormone-arginine-stimulated growth hormone is inversely associated with intramyocellular and intrahepatic lipid content in premenopausal women with obesity. J Clin Endocrinol Metab 94:3995–4002
Mekala KC, Tritos NA (2009) Effects of recombinant human growth hormone therapy in obesity in adults: a meta analysis. J Clin Endocrinol Metab 94:130–137
Ahn CW, Kim CS, Nam JH et al (2006) Effects of growth hormone on insulin resistance and atherosclerotic risk factors in obese type 2 diabetic patients with poor glycaemic control. Clin Endocrinol (Oxf) 64:444–449
Karimi M, Koranyi J, Franco C et al (2010) Increased neck soft tissue mass and worsening of obstructive sleep apnea after growth hormone treatment in men with abdominal obesity. J Clin Sleep Med 6:256–263
Makimura H, Feldpausch MH, Rope AM et al (2012) Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab 97:4769–4779
Camastra S, Manco M, Frascerra S et al (2009) Daylong pituitary hormones in morbid obesity: effects of bariatric surgery. Int J Obes (Lond) 33:166–172
Mancini MC, Costa AP, de Melo ME et al (2006) Effect of gastric bypass on spontaneous growth hormone and ghrelin release profiles. Obesity (Silver Spring) 14:383–387
Galli G, Pinchera A, Piaggi P et al (2012) Serum insulin-like growth factor-1 concentrations are reduced in severely obese women and raise after weight loss induced by laparoscopic adjustable gastric banding. Obes Surg 22:1276–1280
Mittempergher F, Pata G, Crea N et al (2013) Preoperative prediction of growth hormone (GH)/insulin-like growth factor-1 (IGF-1) axis modification and postoperative changes in candidates for bariatric surgery. Obes Surg 23:594–601
De Marinis L, Bianchi A, Mancini A et al (2004) Growth hormone secretion and leptin in morbid obesity before and after biliopancreatic diversion: relationships with insulin and body composition. J Clin Endocrinol Metab 89:174–180
Edén Engström B, Burman P, Holdstock C et al (2006) Effects of gastric bypass on the GH/IGF-I axis in severe obesity–and a comparison with GH deficiency. Eur J Endocrinol 154:53–59
Savastano S, Angrisani L, Di Somma C et al (2010) Relationship between growth hormone/insulin-like growth factor-1 axis integrity and voluntary weight loss after gastric banding surgery for severe obesity. Obes Surg 20:211–220
Savastano S, Di Somma C, Angrisani L et al (2009) Growth hormone treatment prevents loss of lean mass after bariatric surgery in morbidly obese patients: results of a pilot, open, prospective, randomized, controlled study. J Clin Endocrinol Metab 94:817–826
Acknowledgments
We are very grateful to Prof. P. Forestieri (Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy), Prof. L. Angrisani (General and Laparoscopic Surgery Unit, San Giovanni Bosco Hospital, Naples, Italy), Prof. L. Docimo (Division of General and Bariatric Surgery, Second University of Naples, Naples, Italy), Prof. M. Musella (Department of General Surgery, Advanced Biomedical Sciences, University Federico II, Naples, Italy), and Dr. C. Giardiello (Mininvasive and Metabolic Surgery Unit, University, Pineta Grande Hospital, Castel Volturno (CE), Italy) for their long-lasting enthusiastic cooperation in sharing with us the difficult task to investigate the GH/IGF-1 axis in obese patients eligible for surgery.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Colao, A., Savastano, S., Di Somma, C. (2015). Hypothalamic Growth Hormone/IGF-1 Axis. In: Lenzi, A., Migliaccio, S., Donini, L. (eds) Multidisciplinary Approach to Obesity. Springer, Cham. https://doi.org/10.1007/978-3-319-09045-0_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-09045-0_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-09044-3
Online ISBN: 978-3-319-09045-0
eBook Packages: MedicineMedicine (R0)